Gilead Sciences stock nears its all-time high
In the latest supply deal on the active pharmaceutical ingredients (API) front, Gilead Sciences has tapped South Korea’s ...
Defendant Yisel Lopez has been found in contempt for violating an asset freeze order through the sale of property.
Armed with readouts from the PURPOSE 1 and 2 trials, Gilead Sciences is now gearing up for global regulatory submissions for ...
Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the ...
By Rebecca Robbins and Sheryl Gay Stolberg A jury sided with Gilead Sciences in a dispute over whether the government could claim a share of profits from drugs seen as crucial to ending the H.I.V ...
The Mumbai-based non-government entity called Sankalp Rehabilitation Trust, which works with HIV-positive people, had opposed ...
J.P. Morgan analyst Chris Schott has maintained their bullish stance on GILD stock, giving a Buy rating on September 13. Chris Schott has ...
GlobalData on MSN4d
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravirGilead Sciences’ capsid inhibitor lenacapavir has the most competitive potential in long-acting combination regimens in HIV, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback